Cargando…

Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results

IMPORTANCE: Diabetic men appear to have a lower risk of prostate cancer. Whether antidiabetic medications are protective or potentially mask prostate cancer by lowering prostate-specific antigen (PSA) levels is unclear. OBJECTIVE: To examine the associations of antidiabetic medication use with (1) P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beckmann, Kerri, Crawley, Danielle, Nordström, Tobias, Aly, Markus, Olsson, Henrik, Lantz, Anna, Binti Abd Jalal, Noor, Garmo, Hans, Adolfsson, Jan, Eklund, Martin, Van Hemelrijck, Mieke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2019
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6865613/ https://www.ncbi.nlm.nih.gov/pubmed/31693126 http://dx.doi.org/10.1001/jamanetworkopen.2019.14689

Ejemplares similares

Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?
por: Beckmann, Kerri, et al.
Publicado: (2019)

Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: a population-based case-control study
por: Lin, E., et al.
Publicado: (2020)

Association of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer With Cardiovascular Disease Risk and Hypertension in Men With Diabetes
por: Lin, E., et al.
Publicado: (2022)

Use of Warfarin or Direct Oral Anticoagulants and Risk of Prostate Cancer in PCBaSe: A Nationwide Case-Control Study
por: Parker, Jonathan, et al.
Publicado: (2020)

A case-control study of lower urinary-tract infections, associated antibiotics and the risk of developing prostate cancer using PCBaSe 3.0
por: Russell, Beth, et al.
Publicado: (2018)

Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study
por: Lin, E., et al.
Publicado: (2021)

Chronic inflammatory diseases, anti-inflammatory medications and risk of prostate cancer: a population-based case-control study
por: Beckmann, Kerri, et al.
Publicado: (2019)

Association between atherogenic lipids and GnRH agonists for prostate cancer in men with T2DM: a nationwide, population-based cohort study in Sweden
por: Lin, E., et al.
Publicado: (2022)

Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer
por: Crawley, Danielle, et al.
Publicado: (2016)

Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study
por: Crawley, Danielle, et al.
Publicado: (2018)

Effects of increasing the PSA cutoff to perform additional biomarker tests before prostate biopsy
por: Nordström, Tobias, et al.
Publicado: (2017)

A systematic review of the literature exploring the interplay between prostate cancer and type two diabetes mellitus
por: Crawley, Danielle, et al.
Publicado: (2018)

Quantifying the Evidence for the Risk of Metabolic Syndrome and Its Components following Androgen Deprivation Therapy for Prostate Cancer: A Meta-Analysis
por: Bosco, Cecilia, et al.
Publicado: (2015)

Does a novel diagnostic pathway including blood-based risk prediction and MRI-targeted biopsies outperform prostate cancer screening using prostate-specific antigen and systematic prostate biopsies? - protocol of the randomised study STHLM3MRI
por: Nordström, Tobias, et al.
Publicado: (2019)

Mortality in men with castration‐resistant prostate cancer—A long‐term follow‐up of a population‐based real‐world cohort
por: Khoshkar, Yashar, et al.
Publicado: (2021)

Causes of death in men with localized prostate cancer: a nationwide, population‐based study
por: Van Hemelrijck, Mieke, et al.
Publicado: (2015)

Predictors of adverse pathology on radical prostatectomy specimen in men initially enrolled in active surveillance for low-risk prostate cancer
por: Björnebo, Lars, et al.
Publicado: (2020)

Risk of progression following a negative biopsy in prostate cancer active surveillance
por: Beckmann, Kerri, et al.
Publicado: (2022)

Are Prostate Specific-Antigen (PSA) and age associated with the risk of ISUP Grade 1 prostate cancer? Results from 72 996 individual biopsy cores in 6 083 men from the Stockholm3 study
por: Palsdottir, Thorgerdur, et al.
Publicado: (2019)

Mortality following Hip Fracture in Men with Prostate Cancer
por: Van Hemelrijck, Mieke, et al.
Publicado: (2013)

Cost-effectiveness of Prostate Cancer Screening Using Magnetic Resonance Imaging or Standard Biopsy Based on the STHLM3-MRI Study
por: Hao, Shuang, et al.
Publicado: (2022)

Understanding reasons for non-adherence to active surveillance for low-intermediate risk prostate cancer
por: Beckmann, Kerri, et al.
Publicado: (2021)

Developing a consensus statement for psychosocial support in active surveillance for prostate cancer
por: Beckmann, Kerri, et al.
Publicado: (2022)

Use of Antiepileptic Drugs and Risk of Prostate Cancer: A Nationwide Case-Control Study in Prostate Cancer Data Base Sweden
por: George, Gincy, et al.
Publicado: (2023)

Digital Rectal Examination in Stockholm3 Biomarker-based Prostate Cancer Screening
por: Andersson, Joel, et al.
Publicado: (2022)

Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden
por: Van Hemelrijck, Mieke, et al.
Publicado: (2010)

Incorporating Magnetic Resonance Imaging and Biomarkers in Active Surveillance Protocols - Results From the Prospective Stockholm3 Active Surveillance Trial (STHLM3AS)
por: Olsson, Henrik, et al.
Publicado: (2020)

Biochemical Recurrence and Risk of Mortality Following Radiotherapy or Radical Prostatectomy
por: Falagario, Ugo Giovanni, et al.
Publicado: (2023)

The impact of different prostate-specific antigen (PSA) testing intervals on Gleason score at diagnosis and the risk of experiencing false-positive biopsy recommendations: a population-based cohort study
por: Palsdottir, Thorgerdur, et al.
Publicado: (2019)

Association Between Vitamin D and Novel SARS-CoV-2 Respiratory Dysfunction – A Scoping Review of Current Evidence and Its Implication for COVID-19 Pandemic
por: Santaolalla, Aida, et al.
Publicado: (2020)

Effect of information on prostate biopsy history on biopsy outcomes in the era of MRI-targeted biopsies
por: Lantz, Anna, et al.
Publicado: (2020)

Androgen deprivation therapy for prostate cancer and risk of dementia
por: Robinson, David, et al.
Publicado: (2019)

Modeling Disease Trajectories for Castration-resistant Prostate Cancer Using Nationwide Population-based Data
por: Ventimiglia, Eugenio, et al.
Publicado: (2022)

Frequency of Biopsy and Tumor Grade Before vs After Introduction of Prostate Magnetic Resonance Imaging
por: Robinson, David, et al.
Publicado: (2023)

Cohort Profile Update: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base—a refined prostate cancer trajectory
por: Van Hemelrijck, Mieke, et al.
Publicado: (2016)

How to model temporal changes in comorbidity for cancer patients using prospective cohort data
por: Lindhagen, Lars, et al.
Publicado: (2015)

How to measure temporal changes in care pathways for chronic diseases using health care registry data
por: Ventimiglia, Eugenio, et al.
Publicado: (2019)

Variation in Prostate-Specific Antigen Testing Rates and Prostate Cancer Treatments and Outcomes in a National 20-Year Cohort
por: Bergengren, Oskar, et al.
Publicado: (2021)

Are you now a good surgeon? T2 positive margin status as a quality outcome measure following radical prostatectomy
por: Damani, Arees, et al.
Publicado: (2016)

Risk of in-hospital complications after radical cystectomy for urinary bladder carcinoma: population-based follow-up study of 7608 patients
por: Hemelrijck, Mieke, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_34ei3ri22prcp36q3860vkoaf3